Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

ne tablets in delaying the development of definite MS.

In the study, Cladribine tablets are given in two or four treatment cycles in the first year, with each cycle consisting of once daily administration for four to five consecutive days, which means study patients take Cladribine tablets for only 8 to 20 days during that year. In the second year, two treatment cycles are administered to all patient groups.

The primary endpoint of the ORACLE MS trial is time to conversion to MS, according to the McDonald criteria. Other endpoints include time to conversion to clinically definite MS according to the Poser criteria (the main secondary endpoint), assessments of MRI brain scans, and disability progression.

Approximately 200 medical centers globally are expected to participate in this trial.

(1) CLARITY: Cladribine Tablets Treating MS Orally

About Cladribine tablets

Merck Serono's proprietary oral formulation of Cladribine is currently being evaluated in Phase III as a treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS.

About Rebif(R)

Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif(R) in chronic progressive MS has not been established. Interferons are thought to help modulate the body's immune system and reduce inflammation. The exact mechanism is unknown.

Rebif(R), which was approved in Europe in 1998 and in the US in 2002, is registered in more than 80 countries worldwide. Rebif(R) has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area*. Rebif(
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
... 29, 2012 Keryx Biopharmaceuticals, Inc. (NASDAQ: ... development and commercialization of medically important pharmaceutical products for ... disease (the "Company"), today announced its results for the ... At December 31, 2011, the Company had cash, ...
... Feb. 29, 2012  Amgen (NASDAQ: AMGN ) ... Annual Healthcare Conference on Monday, March 5, 2012 at ... approximately 2:50 p.m. Eastern Standard Time.  Jonathan M. Peacock, ... will present. Live audio of the presentation can be ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results 5
(Date:7/12/2014)... 12, 2014 Casinos in ... rising competition from international and online casinos. Revenue is ... the five years through 2014-15. Greater per capita gambling ... gaming services. Rises in discretionary income levels have also ... on non-essential items such as casino gambling services. Revenue ...
(Date:7/12/2014)... Pittsburgh, PA (PRWEB) July 12, 2014 "The ... so it’s uncomfortable and painful to wear shoes," said an ... a special sock that prevents this from happening. , He ... an effective way to prevent the second and big toes ... more endurance while wearing shoes. Ergonomic and easy to use, ...
(Date:7/12/2014)... Using and carrying around a catheter bag ... Ashland, Va., decided that there needed to be an ... conceive of our design," he said. , They then ... provides an inconspicuous way to use and carry a ... promotes comfort and peace of mind. Producible in design ...
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 For those ... are bodies can readily absorb the nutrients in food. The ... particles that are small enough to be absorbed by human ... team, a lack of enzymes in regular food is the ... a product that was started by Michelle DelPresto, a mother ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Doylestown ... covering a variety of men’s health questions. Paddock ... specific to men, why women live longer than men, ... Men's Health Made Simple featured on Doylestown ... get a hernia at any age. If you notice ...
Breaking Medicine News(10 mins):Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... Cancer Research Insitiute, UK suggests that women on tamoxifen have ... They report on a large scale trial of tamoxifen to ... to 65 years, from the UK, Australia, New Zealand and ... the women were considered as being at increased risk of ...
... effective delivery of drugs for a number of conditions. According to ... with the use of nasal sprays to treat allergies such as ... of delivering a drug, because it gets into the bloodstream fast ... fact, act quicker than the corresponding pill. Nasal sprays are already ...
... can control a stressful situation makes it easier on ... is potentially damaging to health because it increases blood ... responses may accumulate to increase the risk of heart ... stress is moderated by many psychological factors, such as ...
... that reduces the level of copper in the blood ... animals. Wilson's disease is a rare disorder where patients ... bodies. Researchers at the University of Texas, through research ... as tetrathiomolybdate (TM) that could fight cancer by lowering ...
... could be used to treat heart and lung disease. ... experiment in healthy young men,// the results of which ... and lung disease. ,They report that the ... hypertension (caused by conditions such as heart valve disease, ...
... in the American Journal of Clinical Nutrition it was observed ... the build up of plaque in the arteries that can ... can protect against the formation of plaque in the arteries. ... diagnosed with heart disease or who had suffered a heart ...
Cached Medicine News:
... easiest, most flexible meter for ... in hospitals. Accu-Chek Inform System ... It is the only Point ... allows for the entry and ...
... the NEXES Special Stains automated ... protocols to provide enhanced consistency ... silver stains. Proprietary kinetic technology, ... Vortex™ Mixing, assures high quality ...
... MTS and the University of Washington ... assessment online for the clinical lab ... training and continuing education include Safety, ... Microbiology. Competency Assessment tests feature high-resolution ...
... a nonprofit, physician-directed organization promoting quality ... care through programs of voluntary education, ... professionals in all sizes of medical ... accreditation, quality management services, consultation in ...
Medicine Products: